Amicus Therapeutics, Inc. (FOLD)
NASDAQ: FOLD · Real-Time Price · USD
14.37
+0.04 (0.28%)
At close: Feb 27, 2026, 4:00 PM EST
14.35
-0.02 (-0.14%)
After-hours: Feb 27, 2026, 6:15 PM EST
Amicus Therapeutics Employees
Amicus Therapeutics had 511 employees as of December 31, 2025. The number of employees increased by 12 or 2.40% compared to the previous year.
Employees
511
Change (1Y)
12
Growth (1Y)
2.40%
Revenue / Employee
$1,241,115
Profits / Employee
-$53,053
Market Cap
4.51B
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| ACADIA Pharmaceuticals | 654 |
| Crinetics Pharmaceuticals | 437 |
| TG Therapeutics | 374 |
| Structure Therapeutics | 218 |
| Apogee Therapeutics | 196 |
| Scholar Rock Holding | 128 |
| CG Oncology | 113 |
| Erasca | 103 |
FOLD News
- 8 days ago - Amicus Therapeutics Announces Full-Year 2025 Financial Results and Corporate Updates - GlobeNewsWire
- 25 days ago - Amicus Therapeutics Presents New Long-term Data for both Galafold® (migalastat) and POMBILITI® (cipaglucosidase alfa-atga) + OPFOLDA® (miglustat) at the 22nd Annual WORLDSymposium™ 2026 - GlobeNewsWire
- 26 days ago - Top 3 Health Care Stocks That May Implode In Q1 - Benzinga
- 2 months ago - Amicus Therapeutics Investment Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Amicus Therapeutics, Inc. - FOLD - Business Wire
- 2 months ago - BioMarin: Amicus Buyout Sparks My Enthusiasm - Seeking Alpha
- 2 months ago - BioMarin is Buying a Rare-Disease Biotech for Nearly $5 Billion. The Stock Is Jumping. - Barrons
- 2 months ago - BioMarin to Buy Amicus Therapeutics for $4.8 Billion - WSJ
- 2 months ago - BioMarin to acquire Amicus Therapeutics for $4.8 Billion - Reuters